Pacer Advisors’s Spyre Therapeutics SYRE Stock Holding History

Pacer Advisors’s Portfolio SYRE Stock Details SYRE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-382	Closed	-$8.98K	–	2694
2024 Q2	$8.98K	Buy	+382	New	+$12.9K	﹤0.01%	3566

Other funds holding SYRE

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

FFM

Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return

Commodore Capital New York $1.73B AUM 298.96% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Pacer Advisors's SYRE Position: Q3 2024 in Review

Pacer Advisors sold out of Spyre Therapeutics (SYRE) in Q3 2024, closing a stake of 382 shares — an estimated $8.98K sold.

Pacer Advisors first reported a position in SYRE in Q2 2024 and held it in 1 quarter. The position peaked at $8.98K in Q2 2024. 119 funds tracked by Wall St. Rank hold SYRE as of Q3 2024.

Pacer Advisors reported no remaining Spyre Therapeutics position as of Q3 2024 after selling out during the quarter.
Pacer Advisors sold 382 Spyre Therapeutics shares in Q3 2024, an estimated $8.98K.
Pacer Advisors first reported a position in Spyre Therapeutics in Q2 2024 and held it in 1 quarter.
Pacer Advisors's Spyre Therapeutics position peaked at $8.98K in Q2 2024.
119 funds tracked by Wall St. Rank held Spyre Therapeutics as of Q3 2024.

Based on Pacer Advisors's 13F filing for Q3 2024, filed 12 Nov 2024.